NO924271L - Vaksiner med forbedret immunogenisitet - Google Patents

Vaksiner med forbedret immunogenisitet

Info

Publication number
NO924271L
NO924271L NO92924271A NO924271A NO924271L NO 924271 L NO924271 L NO 924271L NO 92924271 A NO92924271 A NO 92924271A NO 924271 A NO924271 A NO 924271A NO 924271 L NO924271 L NO 924271L
Authority
NO
Norway
Prior art keywords
vaccines
improved immunogenicity
immunoadjuvant
immunogen
activating
Prior art date
Application number
NO92924271A
Other languages
English (en)
Norwegian (no)
Other versions
NO924271D0 (no
Inventor
Christopher L Penny
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of NO924271D0 publication Critical patent/NO924271D0/no
Publication of NO924271L publication Critical patent/NO924271L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
NO92924271A 1990-05-07 1992-11-06 Vaksiner med forbedret immunogenisitet NO924271L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51846090A 1990-05-07 1990-05-07
PCT/CA1991/000144 WO1991016926A1 (en) 1990-05-07 1991-05-01 Vaccine compositions

Publications (2)

Publication Number Publication Date
NO924271D0 NO924271D0 (no) 1992-11-06
NO924271L true NO924271L (no) 1993-01-07

Family

ID=24064028

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924271A NO924271L (no) 1990-05-07 1992-11-06 Vaksiner med forbedret immunogenisitet

Country Status (22)

Country Link
EP (1) EP0597838B1 (da)
JP (1) JPH05506234A (da)
CN (1) CN1056816A (da)
AT (1) ATE173936T1 (da)
AU (1) AU7777991A (da)
CA (1) CA2082425A1 (da)
CS (1) CS131891A3 (da)
DE (1) DE69130576T2 (da)
DK (1) DK0597838T3 (da)
ES (1) ES2124701T3 (da)
FI (1) FI925032A0 (da)
HR (1) HRP930658A2 (da)
HU (1) HUT65493A (da)
IE (1) IE911527A1 (da)
IL (1) IL97985A0 (da)
MX (1) MX172210B (da)
NO (1) NO924271L (da)
NZ (1) NZ238042A (da)
TW (1) TW221676B (da)
WO (1) WO1991016926A1 (da)
YU (1) YU79691A (da)
ZA (1) ZA913214B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2004032824A2 (en) * 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd. Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen

Also Published As

Publication number Publication date
WO1991016926A1 (en) 1991-11-14
NZ238042A (en) 1993-12-23
CS131891A3 (en) 1992-02-19
HU9203480D0 (en) 1993-01-28
FI925032L (fi) 1992-11-06
DE69130576D1 (de) 1999-01-14
NO924271D0 (no) 1992-11-06
EP0597838B1 (en) 1998-12-02
HUT65493A (en) 1994-06-28
ATE173936T1 (de) 1998-12-15
CN1056816A (zh) 1991-12-11
ZA913214B (en) 1992-09-30
FI925032A7 (fi) 1992-11-06
EP0597838A1 (en) 1994-05-25
DK0597838T3 (da) 1999-08-16
DE69130576T2 (de) 1999-07-29
ES2124701T3 (es) 1999-02-16
HRP930658A2 (en) 1997-12-31
YU79691A (sh) 1994-06-10
AU7777991A (en) 1991-11-27
IL97985A0 (en) 1992-06-21
CA2082425A1 (en) 1991-11-08
TW221676B (da) 1994-03-11
JPH05506234A (ja) 1993-09-16
IE911527A1 (en) 1991-11-20
MX172210B (es) 1993-12-07
FI925032A0 (fi) 1992-11-06

Similar Documents

Publication Publication Date Title
NO930938L (no) Forbedrede vaksiner
DK1149589T3 (da) Proteinadjuvanser
NO942490L (no) Urease-basert vaksine mot Heliobacter-infeksjon
CH614718A5 (en) Process for the preparation of glucosamine derivatives
RU94042386A (ru) Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита
DK0578293T3 (da) E. coli-P-fimbrin som immunogent bæresystem mod GnRH
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции
RU92016460A (ru) Вакцинная композиция, способ индукции иммунной реакции